Literature DB >> 32908830

High-Titre ANA Positivity in NAFLD: An Uncommon Presentation of a Common Disease.

Asis Mitra1, Saswati Ray2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and has emerged as a serious public health challenge. About 20% of NAFLD patients may have low titres (<1:320) of antinuclear antibodies (ANA). However, we describe a patient with NAFLD whose ANA titre was high (>1:320) on presentation. After 3 months of diet, exercise and vitamin E supplementation, the patient was symptomatically better but her ANA titre had increased (>1:640). Her liver biopsy showed features of NAFLD with minimal fibrosis. High-titre ANA (>1:320) positivity is rare. Our patient showed a progressive rise in ANA titre from >1:320 to >1:640 within 3 months even though she was improving and histology showed minimal fibrosis. LEARNING POINTS: Up to 30% of patients with non-alcoholic fatty liver disease (NAFLD) may have antinuclear antibodies (ANA).Low titre (<1:320) ANA positivity is not uncommon, but a high titre is rare.The ANA titre does not correlate with the histological grade of NAFLD. © EFIM 2020.

Entities:  

Keywords:  Antinuclear antibody; autoimmune hepatitis; liver biopsy; non-alcoholic fatty liver disease

Year:  2020        PMID: 32908830      PMCID: PMC7473677          DOI: 10.12890/2020_001714

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  7 in total

1.  Liver biopsy.

Authors:  Don C Rockey; Stephen H Caldwell; Zachary D Goodman; Rendon C Nelson; Alastair D Smith
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

2.  Autoimmune Markers Do Not Impact Clinical Presentation or Natural History of Steatohepatitis-Related Liver Disease.

Authors:  Sujan Ravi; Mohamed Shoreibah; Evan Raff; Joseph Bloomer; Donny Kakati; Khalid Rasheed; Ashwani K Singal
Journal:  Dig Dis Sci       Date:  2015-07-15       Impact factor: 3.199

Review 3.  Histological assessment of non-alcoholic fatty liver disease.

Authors:  S G Hübscher
Journal:  Histopathology       Date:  2006-11       Impact factor: 5.087

4.  Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan.

Authors:  Yoshio Sumida; Yuichiro Eguchi; Masafumi Ono
Journal:  World J Hepatol       Date:  2010-10-27

5.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

6.  The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease.

Authors:  Leon A Adams; Keith D Lindor; Paul Angulo
Journal:  Am J Gastroenterol       Date:  2004-07       Impact factor: 10.864

Review 7.  Antinuclear antibodies in healthy people and non-rheumatic diseases - diagnostic and clinical implications.

Authors:  Bogna Grygiel-Górniak; Natalia Rogacka; Mariusz Puszczewicz
Journal:  Reumatologia       Date:  2018-08-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.